Skip to content

Post market clinical follow-up study with the EMPOWR 3D

Post market clinical follow-up study with the EMPOWR 3D

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032336
Enrollment
250
Registered
2025-05-26
Start date
2026-01-12
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M17

Interventions

Group 1: All patients undergo total knee arthroplasty with an EMPOWR 3D knee System (Encore Medical, L.P.). Clinical and radiological short-to long-term safety and performance are collected after 3 or

Sponsors

Mathys Ltd Bettlach
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patient has given his/her written consent to participate after having been fully informed (informed consent of the patient) is a candidate for a primary bicondylar knee endoprosthesis suffers from a painful and / or disabling bicompartmental joint disease in the femorotibial compartment resulting from osteoarthritis, avascular necrosis, or post-traumatic arthritis The patient is willing to participate in the follow-up examinations mentioned

Exclusion criteria

Exclusion criteria: Missing informed consent form (signed by participant and investigator) Incapacitated subjects (individuals who are not able to give informed consent due to a mental disability) Minors (< 18 years) Is pregnant, desires to have children or is in the breast-feeding period during the study period Patients in emergency situations (includes sudden life-threatening or other sudden serious medical condition (e.g. unconsciousness) preventing the patient from giving informed consent Known or suspected non-compliance of eligibility criteria (e.g. drug or alcohol abuse) Simultaneous participation in another clinical study or documentation with medical devices or drugs which could have an influence on the current study Non-compliance with clinical investigation-related processes (such as diagnosis and therapy). Enrolment of the investigator, his/her family, employees (MAB/ investigational site) and other dependent persons Geriatric subjects at inclusion Prisoners at inclusion Other patient groups considered particularly vulnerable to such substances and/or materials Infection (or a history of infection), acute or chronic, local or systemic Insufficient bone quality which may affect the stability of the implant Muscular, neurological or vascular deficiencies, which compromise the affected extremity Obesity Loss of ligamentous structures Insufficient soft tissue integrity to provide adequate stability High levels of physical activity (e.g. competitive sports, heavy physical labor) Less understanding of the German language which will be used within questionnaires

Design outcomes

Primary

MeasureTime frame
The primary endpoint of this study will be the New Knee Society Score (NKSS), evaluated at two years postoperatively.

Secondary

MeasureTime frame
The secondary endpoints will be the radiographic evaluation, the Visual Analogue Scale (VAS) measuring pain, VAS measuring satisfaction, Forgotten Joint Score (FJS-12) and Short Form-12 (SF-12).

Countries

Germany

Contacts

Public ContactGeorgi Wassilew

Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Orthopädie und Orthopädische Chirurgie

georgi.wassilew@med.uni-greifswald.de+49 (0)3834 86 7051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026